Longhi A, Errani C, Magagnoli G, Alberghini M, Gambarotti M, Mercuri M, Ferrari S
Musculoskeletal Department, Chemotherapy Division, Istituto Ortopedico Rizzoli, Bologna, Italy.
J Chemother. 2010 Dec;22(6):413-8. doi: 10.1179/joc.2010.22.6.413.
Malignant peripheral nerve sheath tumours (MPNST) are rare sarcomas with one of the poorest prognoses of all the soft tissue sarcomas. Information about adjuvant treatment is scarce and not homogeneous for this diagnosis. We analyzed retrospectively the outcome of patients with localized high grade MPNST admitted to our institute from 1969 to 2008. A review of the literature is also reported. Of 62 evaluable patients, 23 were females and 39 males, median age 39 years (17-71), 22/62 had neurofibromatosis type I. Median follow-up was 54 months (range 12-194). A total of 22/62 are alive; 26 patients had surgery alone, 18 received radiation therapy, 12 received radiation therapy and chemotherapy, and 6 received only adjuvant chemotherapy. The 5-year disease-free survival was 30% and 5-year overall survival was 38%. A positive trend for adjuvant radiation, but not for chemotherapy was observed according to univariate analysis only for disease-free survival and overall survival. Multivariate analysis indicated that primary site, size and surgical margins remained significant for disease-free survival and only site and size were significant for overall survival. New drugs employed successfully in advanced mpNSt should be employed also in the adjuvant setting.
恶性外周神经鞘瘤(MPNST)是一种罕见的肉瘤,在所有软组织肉瘤中预后最差。关于辅助治疗的信息稀缺,且针对该诊断的信息并不统一。我们回顾性分析了1969年至2008年收治入我院的局限性高级别MPNST患者的预后情况。同时也报道了文献综述。在62例可评估患者中,女性23例,男性39例,中位年龄39岁(17 - 71岁),62例中有22例患有I型神经纤维瘤病。中位随访时间为54个月(范围12 - 194个月)。62例中共有22例存活;26例仅接受了手术,18例接受了放射治疗,12例接受了放射治疗和化疗,6例仅接受了辅助化疗。5年无病生存率为30%,5年总生存率为38%。仅单因素分析显示,辅助放疗对无病生存率和总生存率有积极趋势,但化疗无此趋势。多因素分析表明,原发部位、大小和手术切缘对无病生存率仍有显著影响,而对总生存率仅有部位和大小有显著影响。在晚期MPNST中成功应用的新药也应在辅助治疗中使用。